iBio
IBIO
iBio (IBIO) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Chardan Capital | Maintained | Buy | $5.00 | Jul 2, 2026 |
| Raymond James | Initiated Coverage | Outperform | $5.00 | Jun 8, 2026 |
| Chardan Capital | Maintained | Buy | $5.00 | Apr 9, 2026 |
| Chardan Capital | Maintained | Buy | $5.00 | Mar 18, 2026 |
| Jones Trading | Initiated Coverage | Buy | $7.00 | Mar 3, 2026 |
| Chardan Capital | Maintained | Buy | $5.00 | Feb 12, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $5.00 | Oct 21, 2025 |
| Leerink Partners | Initiated Coverage | Outperform | $2.00 | Oct 17, 2025 |
| Chardan Capital | Maintained | Buy | $5.00 | Jun 25, 2025 |
| Chardan Capital | Maintained | Buy | $5.00 | May 6, 2025 |
| Chardan Capital | Maintained | Buy | $5.00 | May 5, 2025 |
Frequently asked questions
What is the latest analyst rating on IBIO?
On Jul 2, 2026, Chardan Capital maintained iBio at Buy with a price target of $5.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.